Albireo Pharma (ALBO) Reports FY16 Loss of $13.16
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 11/4/2026
- Wall Street ends higher after Democrats win Congress; data center stocks tumble
- What the Democratic sweep in the midterms means for markets
- SpaceX, Tesla slide as election risks mount, Morgan Stanley turns bullish
- CVS Health plans to split into two public companies by 2028
- AI sector outlook darkens as Democrat wins threaten $900B capex cycle
Tweet
Share
E-mailGet Alerts ALBO Hot Sheet
Join SI Premium – FREE
Albireo Pharma (NASDAQ: ALBO) reported FY16 EPS of ($13.16), versus ($25.49) reported last year. Revenue for the year came in at $11.4 million, versus $5.1 million reported last year.
For earnings history and earnings-related data on Albireo Pharma (ALBO) click here.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- Vertex (VERX) Tops Q3 EPS by 4c; Offers Guidance
- Veeco Instruments (VECO) Misses Q3 EPS by 9c; Offers Guidance
- Solid Biosciences (SLDB) Tops Q3 EPS by 5c
Create E-mail Alert Related Categories
Earnings, GuidanceRelated Entities
EarningsSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
